Acadia, deCODE: Venture Bets On Comeback Kids Pay Off
This article was originally published in Start Up
Two long-in-the-tooth biotechs, Acadia and deCODE, were desperate for help. The venture investors who helped bail them out have seen their investments pay off nicely. Promising Phase III data for its lead compound have boosted Acadia’s stock, and Amgen spent generously to buy deCODE’s genetic expertise for its own drug discovery efforts.
You may also be interested in...
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.